

ForPatients

by Roche

Multiple Sclerosis (MS) Clinically Isolated Syndrome (CIS)

A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab

Trial Status
Recruiting

Trial Runs In
3 Countries

Trial Identifier
NCT04998851 2021-000063-79
MN42989

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the pharmacokinetics of ocrelizumab in the breastmilk of lactating women with clinically isolated syndrome (CIS) or multiple sclerosis (MS) [in line with the locally approved indications] treated with ocrelizumab, by assessing the concentration of ocrelizumab in mature breastmilk, as well as the corresponding exposure and pharmacodynamic effects (blood B cell levels) in the infants.

Hoffmann-La Roche
Sponsor

Phase 4
Phase

NCT04998851 2021-000063-79 MN42989
Trial Identifiers

Eligibility Criteria:

Gender
Female

Age
≥18 Years & ≤ 40 Years

Healthy Volunteers
No
